More than a decade after coining “Treat Yo’ Self Day” in her role as Donna on “Parks & Recreation,” Retta is once again ...

Little did I realize a few grapes could send my blood sugar soaring until I tried the first glucose monitor without a ...

Wells Fargo analyst Larry Biegelsen maintained a Buy rating on Dexcom (DXCM – Research Report) yesterday and set a price target of ...

DexCom's revised FY24 sales guidance in the Q2 earnings call led to a $18bn valuation reset. Read why I think DXCM stock is a ...

(Nasdaq: DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, today announced the Dexcom G6 Continuous Glucose Monitoring (CGM) System is being worn by ...

Ithaka US Growth Strategy highlighted stocks like DexCom, Inc. (NASDAQ:DXCM), in the second quarter 2024 investor letter. DexCom, Inc. (NASDAQ:DXCM) is a medical device company engages in the ...

Medical device specialist DexCom (NASDAQ: DXCM) is going through a rough patch. The company's shares dropped off a cliff following its second-quarter earnings report. However, zooming out helps ...

DexCom is one of the leaders in an industry with massive growth potential. The company is building a competitive advantage. Despite several risks, it could deliver substantial returns in the long ...

A tiny streaming box tapping into the power of Android, the Fetch Mini Gen 5 (G5) puts the best of broadcast and internet video at your fingertips. For Australians who don’t want to hand over their ...

It costs $99 for two sensors (30 days of use) or $89 per month via subscription. Like most CGMs, Stelo provides 24/7 glucose readings to a smartphone app for up to 15 days. The app offers ...

Dexcom announced the FDA clearance of its Stelo OTC glucose biosensor to consumers without a prescription in March 2024. The G7, the company's most recent CGM sensor, is presently prescribed.